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Sharing the benefits of genetic research
Will the World Trade Organization act to stop the exploitation of biodiversity?
C
ampaigners are calling on policy makers at
next week’s sixth World Trade Organization
ministerial conference in Hong Kong to make
trade fairer for and improve the lives and health of the
world’s poorest people. This broad and important aim
may dominate the headlines, but ministers will also be
discussing technical issues surrounding international
patenting laws. One issue with implications for the
development of medical products is the tension
between international patenting laws and benefit shar-
ing requirements, which may threaten agreements on
protecting biodiversity. If the biodiversity door shuts
because of protests in developing countries, pharma-
ceutical research will be seriously hampered.
In Hong Kong the World Trade Organization can
stop the exploitation of non-human genetic material
and traditional knowledge by aligning the trade related
intellectual property rights (TRIPS) agreement with
the Convention on Biological Diversity. Over the past
decade benefit sharing has become a recurrent theme
in international debates on human and non-human
genetics. The term arose from the Convention on Bio-
logical Diversity adopted at the 1992 earth summit in
Rio de Janeiro, Brazil.1 The convention has three
objectives: the conservation of biological diversity, the
sustainable use of its components, and the fair and
equitable sharing of benefits from the use of genetic
resources (“benefit sharing”). Although benefit sharing
is compulsory when the biosciences industry or
research centres use biodiversity and associated local
or indigenous knowledge to develop new products and
services, it is not covered by legally binding
international trade agreements, such as TRIPS,2 nor
does it cover human genetic resources.
Benefit sharing is particularly important in three
contexts in genetics: access to non-human genetic
resources and associated traditional knowledge, human
genetic banking, and research on rare genotypes.3 The
few benefit sharing agreements that have been signed
to date have been widely criticised (see box on
bmj.com).4–7
Concerns regarding benefit sharing for non-human
genetic resources and traditional knowledge have
included practical problems such as: how can prior
informed consent be obtained from large communities
without adequate means of representation; how can the
socioeducational gap between negotiating partners be
bridged; how can lack of trust between negotiating
partners be overcome; and which benefits should be
made available when and to whom? Principled
objections have included concerns about incompatibility
between the concept of communally owned traditional
knowledge and the intellectual property rights system;
views that sacred knowledge ought never be patented;
and the fear that benefiting individual communities
according to ethnic distinctions is divisive.
These concerns should not detract from the fact
that 187 countries and the European Union have
agreed in the Convention on Biological Diversity that
benefit sharing for non-human genetic resources and
traditional knowledge is legally binding.1 It is in this
context that an earlier ministerial conference of World
Trade Organization members agreed the Doha
Mandate in Qatar in November 2001.8 This mandate
identified the need for further negotiation on the clash
between TRIPS and the Convention on Biological
Diversity. This was reinforced by a series of submissions
to theWorld Trade Organization from a group of Latin
American and Asian countries which suggested how to
bridge the gap between the two agreements.9 These
submissions urged that patent applicants should
provide disclosure of the source and country of origin
of the biological resource and of the traditional knowl-
edge used in the invention; evidence of prior informed
consent through approval of authorities under the rel-
evant national regime; and evidence of fair and equita-
ble benefit sharing under the relevant national regime.
Without the proposed revision of TRIPS, the Con-
vention on Biological Diversity is legally binding but
lacks “teeth” because it does not include the strong
mechanism for dispute settlement that is provided by
World Trade Organization treaties. Ministers will
consider the revision in Hong Kong and are in an
excellent position to stop the exploitation of non-
human genetic resources and traditional knowledge.
Aside from the discussions in Hong Kong, benefit
sharing for human genetic resources is an even greater
challenge, as none of the relevant international guide-
lines are legally binding (HUGO Ethics Committee
statement on benefit sharing,10 UNESCO International
Declaration on Human Genetic Data11). It has therefore
been suggested that the Convention on Biological
Diversity should be extended to include human genetic
Box showing benefit sharing agreements is on bmj.com
Editorials
BMJ 2005;331:1351–2
1351BMJ VOLUME 331 10 DECEMBER 2005 bmj.com
 on 25 February 2009 bmj.comDownloaded from 
resources.12 However, benefit sharing agreements
under the Convention are negotiated locally, between
contracting individuals (“I want your plant, what do you
want in return?”). This market model does not sit com-
fortably with human health needs. Merely expanding
the convention to cover human genetic resources might
serve as “window dressing” for national governments
and detract from efforts to make them regard health
and health research as a state priority and the best eco-
nomic investment they could make.13–15 Instead the
research community should make a concerted effort in
cooperation with national governments to devise a
legally binding framework for sharing the benefits of
human genetics research that is based on equity, justice,
and the spirit of the convention.
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Is methadone too dangerous for opiate addiction?
The case for using a safer alternative, buprenorphine, is strong
M
ethadone is an effective treatment for heroin
addiction, and it remains the mainstay of
drug treatment for opiate dependence in the
United Kingdom.1 The lethal dose of methadone is
estimated at 50 mg for an opiate-naive adult.2
Nevertheless, many authorities recommend that
methadone doses should be gradually increased to
maintenance doses of 80-120 mg1—that is, twice the
lethal dose for non-users. The greatly increased risk to
users from methadone, particularly black market
methadone, thus remains a major concern. Buprenor-
phine is a partial agonist that has a lower potential for
causing respiratory depression than many other opio-
ids, including methadone and heroin.3 It is increasingly
used in the United Kingdom to treat opiate
dependence, with guidelines for clinical management
in primary and secondary care summarised by Ford et
al4 and Taikato et al.5 It is time it replaced methadone as
the mainstay of drug treatment for opiate dependence.
A long running debate continues between propo-
nents of long term maintenance treatment with metha-
done and the proponents of detoxification (in which the
dose of a substitute drug is reduced over time to achieve
abstinence from all agents). An expert US panel
concluded, “although the drug free state represents an
optimal treatment goal, research has demonstrated that
the state cannot be achieved or sustained by the major-
ity of persons dependent on opiates.”6 Without
digressing further into this debate, we point out that that
buprenorphine is at least as effective as methadone in
both maintenance and detoxification.7–9
One mechanism to reduce the diversion of
methadone on to the black market is to insist that these
drugs are taken in the presence of a pharmacist rather
than being given “to take away.” Repeated advice to this
effect is provided by the UK Department of Health and
the Home Office.1 10 We have recently contacted 120 of
the 140 community drug teams in England andWales to
ask what proportion of new patients on methadone
undergo supervised consumption.We found that at least
25% of people who start prescriptions for methadone
are still prescribed methadone to take away. This
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